Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
Status:
RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of avatrombopag in the treatment of pediatric primary immune thrombocytopenia in patients who have been treated with eltrombopag before and switched to avatrobopag because of poor efficacy, excessive platelet fluctuation or intolerance, or patient preference, economic reasons, and other reasons.
Phase:
PHASE2
Details
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Collaborators:
Henan Cancer Hospital The Second Affiliated Hospital of Kunming Medical University Tianjin Children's Hospital Tianjin Medical University Second Hospital